WallStreetZenWallStreetZen

NASDAQ: ANIX
Anixa Biosciences Inc Stock

$3.12-0.11 (-3.41%)
Updated Mar 28, 2024
ANIX Price
$3.12
Fair Value Price
$0.01
Market Cap
$99.53M
52 Week Low
$2.75
52 Week High
$6.45
P/E
-9.18x
P/B
4.05x
P/S
679.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$210.00k
Earnings
-$10.74M
Gross Margin
23.3%
Operating Margin
-5,116.19%
Profit Margin
-5,116.2%
Debt to Equity
0.07
Operating Cash Flow
-$7M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ANIX Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ANIX ($3.12) is overvalued by 42,561.13% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ANIX ($3.12) is not significantly undervalued (42,561.13%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANIX due diligence checks available for Premium users.

Be the first to know about important ANIX news, forecast changes, insider trades & much more!

ANIX News

Valuation

ANIX fair value

Fair Value of ANIX stock based on Discounted Cash Flow (DCF)
Price
$3.12
Fair Value
$0.01
Overvalued by
42,561.13%
ANIX ($3.12) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANIX ($3.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ANIX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-9.18x
Industry
14.26x
Market
44.51x

ANIX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.05x
Industry
6.21x
ANIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ANIX's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
ANIX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ANIX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$25.4M
Liabilities
$1.8M
Debt to equity
0.07
ANIX's short-term assets ($25.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANIX's short-term assets ($25.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANIX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ANIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.3M
Investing
$129.0k
Financing
$2.3M
ANIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ANIX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ANIX$99.53M-3.41%-9.18x4.05x
RZLT$101.04M+13.84%-2.32x1.10x
CELU$101.35M+5.87%-0.52x3.35x
VANI$101.71M0.00%-3.70x4.90x
ANTX$96.66M+0.93%-1.15x0.70x

Anixa Biosciences Stock FAQ

What is Anixa Biosciences's quote symbol?

(NASDAQ: ANIX) Anixa Biosciences trades on the NASDAQ under the ticker symbol ANIX. Anixa Biosciences stock quotes can also be displayed as NASDAQ: ANIX.

If you're new to stock investing, here's how to buy Anixa Biosciences stock.

What is the 52 week high and low for Anixa Biosciences (NASDAQ: ANIX)?

(NASDAQ: ANIX) Anixa Biosciences's 52-week high was $6.45, and its 52-week low was $2.75. It is currently -51.63% from its 52-week high and 13.45% from its 52-week low.

How much is Anixa Biosciences stock worth today?

(NASDAQ: ANIX) Anixa Biosciences currently has 31,899,800 outstanding shares. With Anixa Biosciences stock trading at $3.12 per share, the total value of Anixa Biosciences stock (market capitalization) is $99.53M.

Anixa Biosciences stock was originally listed at a price of $87.50 in Dec 31, 1997. If you had invested in Anixa Biosciences stock at $87.50, your return over the last 26 years would have been -96.43%, for an annualized return of -12.03% (not including any dividends or dividend reinvestments).

How much is Anixa Biosciences's stock price per share?

(NASDAQ: ANIX) Anixa Biosciences stock price per share is $3.12 today (as of Mar 28, 2024).

What is Anixa Biosciences's Market Cap?

(NASDAQ: ANIX) Anixa Biosciences's market cap is $99.53M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Anixa Biosciences's market cap is calculated by multiplying ANIX's current stock price of $3.12 by ANIX's total outstanding shares of 31,899,800.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.